Rarity Bioscience
Founded 2021 · 28 employees on LinkedIn · 2 known investors
Rarity Bioscience develops ultra-sensitive mutation detection assays based on its patented superRCA dual-RCA technology, which amplifies single mutated DNA molecules into fluorescent particles for detection on standard flow cytometers. The research-use-only platform targets researchers working on measurable residual disease assessment, relapse and resistance detection, therapy response research, and drug development.
Investors · 2
Frequently asked questions
- What does Rarity Bioscience do?
- Rarity Bioscience develops ultra-sensitive mutation detection assays based on its patented superRCA dual-RCA technology, which amplifies single mutated DNA molecules into fluorescent particles for detection on standard flow cytometers. The research-use-only platform targets researchers working on measurable residual disease assessment, relapse and resistance detection, therapy response research, and drug development.
- Who are Rarity Bioscience's investors?
- Rarity Bioscience's investors include Navigare Ventures, Novalis Biotech.